Category Archives: Multaq

Featured Stories

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Inc. division revealed yesterday that it will end sales of its Gynecare Prolift device and three other transvaginal mesh products. The plan to stop selling the four products was set forth in a letter filed by the company in the Ethicon transvaginal mesh multidistrict litigation ...

Read More

Exposure to Common Pesticide May Increase ADHD Risk

Exposure to Common Pesticide May Increase ADHD Risk

A new study has found that exposure to a common household pesticide may increase the risk of attention deficit hyperactivity disorder (ADHD) in children.

Read More

DePuy ASR Hip Implants, Other Faulty Medical Devices Subject to Little FDA Oversight, Investigation Finds

A newly-published investigation from ProPublica has revealed that several questionable types of medical devices, including DePuy Orthopaedic’s recalled ASR hip implant, managed to make it to market without much scrutiny on the part of the U.S. Food & Drug Administration (FDA).

Read More

Smokers More Vulnerable to Joint Replacement Failures

People who smoke cigarettes before and after receiving a total joint replacement, such as a hip replacement device or knee implant, are far more likely to endure revision surgeries on those implants than people who don’t smoke.

Read More

New York Property Owners Challenge Binghamton Fracking Ban

According to a Reuters report, the landowners believe the Binghamton, N.Y., city council and Mayor acted against proper protocol when voting to ban fracking drilling the the city. Instead, they feel the city should have consulted with the Broome County Planning Commission before approving the ban.

Read More

Post -Tonsillectomy Morphine Life-Threatening in Children

Post -Tonsillectomy Morphine can be Life-Threatening in Children, Study Finds

A new study published in Pediatrics suggests that morphine can result in life-threatening respiratory problems when given to children after a tonsillectomy.

Read More

British Health Agency Strengthens Warnings about Valproate

British Health Agency Strengthens Warnings about Valproate Risk in Pregnancy

Statement issued urging healthcare professionals to give women information on birth defects when Depakote and other valproate medicines are used during pregnancy.

Read More

Former Executives Accuse Health Technology Firm of Fraud

Former Executives Accuse Health Technology Firm of Fraud

Former NantHealth executives claim that the company made fraudulent claims about the reliability of its system, which links patient information gathered by the devices.

Read More

Bleeding Side Effects of Pradaxa, Xarelto Have Some Doctors Concerned

Some heart doctors are raising concerns about a new class of heart drugs that include Pradaxa. Recently, a number of doctors interviewed by Reuters said they were hesitant to prescribe Pradaxa, as well as another blood thinner called Xarelto, because of concerns regarding the risk of stroke, serious bleeding ...

Read More

Federal Judge Certifies Medtronic Infuse Shareholder Class Action Lawsuit

A shareholder lawsuit alleging Medtronic Inc. illegally promoted the off-label use of its Infuse bone growth product has been granted class action status by U.S. District Judge Paul Magnuson of Minnesota. According to a report from Law360.com, the Medtronic Infuse off-label promotion lawsuit was filed by several institutional investors on ...

Read More

Middle-aged Dronedarone Users Have Higher Risk of Hospitalization

Middle-aged Dronedarone Users Have Higher Risk

New study results reveal that patients age 61 and younger treated with the heart rhythm drug dronedarone (Multaq) have a higher risk for hospitalization than those with treated other anti-arrhythmic drugs. The study, published in Circulation: Cardiovascular Quality and Outcomes, … Continue reading

Posted in Health Concerns, Multaq, Pharmaceuticals | Tagged , , , , |

Multaq Patients Had Double Death Risk in Halted Trial

A study has found that patients taking < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Side Effect Concerns Prompt Restrictions in Europe

Use of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, the Sanofi-Aventis heart drug that has been linked to heart, liver and lung problems, has been restricted by regulators in Europe. According to a report from The Wall Street Journal, a committee of the European Medicines … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Faces FDA Scrutiny As Safety Concerns Mount

The U.S. Food & Drug Administration (FDA) said yesterday that it is continuing to review the safety of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, as more and more specialists report they are no longer prescribing the drug. Multaq has been linked to a number … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Maker Issues Formal Alert for Halted Study

Sanofi-Aventis has formally alerted doctors that a clinical trial involving < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) was halted because patients in the study’s Multaq group were dying at more than twice the rate of that of patients taking placebo. “Healthcare professionals are advised … Continue reading

Posted in Multaq, Pharmaceuticals |

Canada Reviewing Multaq Over Heart Worries

Add Canada to the list of countries taking a deeper look into prescription medication, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). Health Canada, said CTV News, is reviewing the drug’s safety. Multaq is already approved to treat temporary Atrial Fibrillation (AF), or abnormal heart … Continue reading

Posted in Multaq |

New Multaq Alert Issued by FDA

Following an expanded European Medicines Agency (EMA) probe, the U.S. Food and Drug Administration (FDA), as expected, announced that it will be reviewing information from a < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq clinical trial that was stopped over higher-than-expected adverse heart reactions in trial … Continue reading

Posted in Multaq |

Multaq Heart Side Effects Under Review in Europe

Sanofi is facing an expansion of an ongoing review of its atrial fibrillation (AF) treatment, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). The European Medicines Agency (EMA) found that a study revealed possible heart risks in patients using the drug, said FiercePharma. The Agency … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Trial Halted Due to Significant Increase in Heart Problems

A clinical trial for < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) has ended early after a significant number of heart-related side effects were seen in the study. The trial, known as the PALLAS study, was testing Multaq’s as a treatment for permanent atrial fibrillation. … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Patients Should Undergo Liver Function Tests

European regulators recently warned that < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (donedarone) could put patients at risk for severe liver injuries. The European Medicines Agency (EMA) is now recommending that doctors perform liver function tests before treating atrial fibrillation patients with Multaq. The European … Continue reading

Posted in Multaq, Pharmaceuticals | Tagged , , , , |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.